Adagene Inc (FRA:978)
€ 2.74 0.34 (14.17%) Market Cap: 121.00 Mil Enterprise Value: 39.13 Mil PE Ratio: 0 PB Ratio: 1.93 GF Score: 19/100

Adagene Inc at EBD Group Biotech Showcase Transcript

Jan 09, 2023 / 07:30PM GMT
Release Date Price: €1.44 (+9.92%)
Unidentified Participant

The next presenting company is Adagene from San Diego, California, United States. Adagene is focused on antibodies, artificial intelligence, immuno-oncology, machine learning, oncology and platform technology. Presenting for Adagene is their co-founder and CEO, Peter Luo.

Peter Luo
Adagene Inc. - CEO

Shall I get started? Okay. Thanks for coming, and good morning. Today, I'd like to introduce Adagene to you and just -- here's our story. We basically have a platform. We combine the computational technology with the gene, and that's why we call the Adagene. This allow us to make very different molecules. And the past -- here's the team we've put together and to execute our visions.

For today's talk, I want to focus a few highlights here. And the first four, we'd like to you to focus our CTLA-4 franchise. And we make two molecules, very different. One is without the masking, the other is with the mask. For the both targeting a very unique epitope. With the [confirmation] epitope, we'll be able to fish out from our computational technology

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot